Senior management team takes over ownership of Quebec-based multinational pharmaceutical group Duchesnay

BLAINVILLE, QUEBEC – November 9, 2021 – The ownership of Duchesnay and its affiliated pharmaceutical companies, based in Blainville, Quebec, have been acquired by its senior management headed by Éric Gervais, President, after more than 25 years as Executive Vice-President. Management has acquired these successful businesses from Pierre Boivin and his family after he expressed his desire to step back to pursue other interests.

Read more

Médunik Canada once again receives Notice of Compliance from Health Canada for Ruzurgi® (amifampridine) following review ordered by court ruling

BLAINVILLE, Quebec (Canada) – June 29, 2021 – Médunik Canada is pleased to announce that Health Canada has reissued the approval (Notice of Compliance) for Ruzurgi® (amifampridine), for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients six years of age or older and has resumed supply in Canada.

Read more

Ruzurgi® Now Available to Canadian Lambert-Eaton Myasthenic Syndrome (LEMS) Patients

BLAINVILLE, Quebec (Canada) – September 25, 2020 – Médunik Canada, a pharmaceutical company dedicated to improving the health and quality of life of Canadians with rare diseases, is extremely pleased to announce that its new orphan disease product Ruzurgi® (amifampridine) is now commercially available to Canadian patients.

Read more

Médunik Canada Expands its Orphan Disease Portfolio by Receiving Market Authorization for Ruzurgi®

BLAINVILLE, Quebec (Canada) – August 18, 2020 – Médunik Canada, a pharmaceutical company dedicated to improving the health and quality of life of Canadians with rare diseases, is extremely pleased to announce that our orphan disease portfolio just expanded further with the recent addition of a new drug. Health Canada has issued a Notice of Compliance (NOC) for Ruzurgi® (amifampridine), a drug indicated for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in patients 6 years of age or older.

Read more

Medunik Canada signs an exclusive agreement with HRA pharma for commercialization of Lysodren® (mitotane) in Canada, for the treatment of inoperable adrenal cortical carcinomas

BLAINVILLE, QC (CANADA), January 16, 2019 — Medunik Canada, a company dedicated to improving the health and quality of life of Canadians living with rare diseases, is proud to announce the signing of a licensing and supply agreement with HRA Pharma. The agreement grants Medunik Canada exclusive commercial rights in Canada for Lysodren®, indicated for the treatment of inoperable functional and non-functional adrenal cortical carcinoma.  

Read more